How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma.
The progression of multiple myeloma (MM), a hematologic malignancy characterized by unregulated plasma cell growth, is associated with increasing innate and adaptive immune system dysfunction, notably in the T-cell repertoire. Although treatment advances in MM have led to deeper and more durable clinical responses, the disease remains incurable for most patients. Therapeutic strategies aimed at overcoming the immunosuppressive tumor microenvironment and activating the host immune system have recently shown promise in MM, particularly in the relapsed and/or refractory disease setting. As the efficacy of T-cell-dependent immuno-oncology therapy is likely affected by the health of the endogenous T-cell repertoire, these therapies may also provide benefit in alternate treatment settings (e.g., precursor disease; after stem cell transplantation). This review describes T-cell-associated changes during the evolution of MM and provides an overview of T-cell-dependent immuno-oncology approaches under investigation. Vaccine and checkpoint inhibitor interventions are being explored across the MM disease continuum; treatment modalities that redirect patient T cells to elicit an anti-MM response, namely chimeric antigen receptor (CAR) T cells and bispecific antibodies (including BiTE [bispecific T-cell engager] molecules), have been primarily evaluated to date in the relapsed and/or refractory disease setting. CAR T cells and bispecific antibodies/antibody constructs directed against B-cell maturation antigen (BCMA) have generated excitement, with clinical data demonstrating deep responses. An increased understanding of the complex interplay between the immune system and MM throughout the disease course will aid in maximizing the potential for T-cell-dependent immuno-oncology strategies in MM.